drugset
Drugs / ARO-ANG3
last change Jul 2026 re-read 3 minutes ago

ARO-ANG3

also known as zodasiran

Small interfering RNA (siRNA) targets ANGPTL3 via inhibition

Developed for
familial hypercholesterolemia · hypertriglyceridemia
Investigated by
Arrowhead Pharmaceuticals

Trials 1

today NCT03747224 · Ph 1
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03747224 Jan 2019 → May 2021 familial hypercholesterolemia, hypertriglyceridemia Arrowhead Pharmaceuticals Completed Met primary

Press releases naming this drug 18 releases

DateIssuerRelease
2026-07-27 Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia arrowheadpharma.com ↗
2025-07-08 Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia arrowheadpharma.com ↗
2024-05-29 Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia arrowheadpharma.com ↗
2023-11-13 Arrowhead Pharmaceuticals Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023 arrowheadpharma.com ↗
2023-05-23 Arrowhead Pharmaceuticals Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH arrowheadpharma.com ↗
2022-10-11 Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3 arrowheadpharma.com ↗
2022-04-26 Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia arrowheadpharma.com ↗
2022-02-24 Arrowhead Pharmaceuticals Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia arrowheadpharma.com ↗
2021-06-30 Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia arrowheadpharma.com ↗
2021-01-25 Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia arrowheadpharma.com ↗
2020-11-04 Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 arrowheadpharma.com ↗
2020-08-31 Arrowhead Pharmaceuticals Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020 arrowheadpharma.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as ARO-ANG3 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03747224 ↗
Known as zodasiran “a 16-week phase 1 trial of zodasiran, an ANGPTL3‑targeting small interfering RNA” PMID 41946917 ↗ Apr 2026
Action Inhibit “ARO-ANG3 treatment reduced ANGPTL3” PMID 37626170 ↗ Aug 2023
Modality Small interfering RNA (siRNA) “zodasiran, an ANGPTL3‑targeting small interfering RNA” PMID 41946917 ↗ Apr 2026
Route Subcutaneous “single or multiple doses of ARO-ANG3 by subcutaneous (sc) injections” NCT03747224 ↗
Target ANGPTL3 “targets angiopoietin-like protein 3 (ANGPTL3)” PMID 37626170 ↗ Aug 2023